Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® (naloxone HCl) Nasal Spray as the first FDA-approved ...

Emergent BioSolutions is rated Buy after a Q3 earnings beat, CEO turnaround progress, and improved financial outlook. Read ...

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November ...

What Happened: Dayal's recent move involves selling 8,552 shares of Emergent BioSolutions. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Monday.

The reduction in Emergent BioSolutions shares by BlackRock suggests a strategic shift or a reallocation within its portfolio. Holding a 3.70% position post-transaction indicates a significant but not ...

Maryland-based Emergent BioSolutions has worked its way to the front lines of the COVID-19 vaccine manufacturing field with a suite of deals to produce U.S. supply. But Emergent has more on its mind ...

SO, YEP YOU GOD I DO AFTER TAKING AN OATH EMERGENT BIOSOLUTIONS CEO OWNED THE PRODUCTION PROBLEMS. IN CORONAVIRUS VACCINE BACK IN MARCH AS CEO, I TAKE FULL RESPONSIBILITY FOR THAT EXECUTIVES FROM THE ...

NYSE:EBS Earnings and Revenue History November 7th 2025 The Impact Of Unusual Items On Profit. To properly understand Emergent BioSolutions' profit results, we need to consider th ...

With BottleRock, Pacifico became the first sponsor of Emergent's video series BKTLST, delivering festival content to Northern California audiences. For the GoPro Mountain Games, l ...

As organizations accelerate their adoption of AI and cloud-native platforms, Emergent is well-positioned to help clients make confident, forward-thinking investments. Their continued focus on ...